The global antibiotic resistance market is expected to reach USD 12.48 billion by 2030, registering a CAGR of 5.27% from 2024 to 2030. Rise in the number of antibiotic-resistant infections due to misuse or overuse of antibiotics is a major factor attributing to market growth. Moreover, the increasing patient base across the globe and high costs associated with the treatment of diseases is anticipated to boost the market growth over the forecast period. ![Global Antibiotic Resistance Market]( "Global Antibiotic Resistance Market")
The prevalence of gram-negative infections is increasing at an alarming rate. These infections have lesser treatment options available in the market. The high unmet needs result in high demand for new therapies and, therefore, small and medium-sized pharmaceutical companies are actively involved in the development of novel treatment options. Moreover, the government and other organizations are also aiding research activities to drive the development of innovative therapies.
Multiple mid-level biotechnology companies have entered the arena with targeted therapies for antibiotic-resistant infections. Various manufacturers are developing therapies, especially for drug-resistant infections, that target a smaller population subset.
The U.S. government in alliance with BARDA is supporting several companies to boost the development of new therapies for antibiotic-resistant diseases. BARDA has also been associated with pharmaceutical companies such as GSK; Tetraphase; Basilea; Astra Zeneca; and many more. Many countries and international organizations have formed dedicated groups or alliances to monitor and study the pattern of drug-resistant infections.
For instance, the WHO has introduced the Global Antimicrobial Resistance Surveillance System (GLASS) to monitor antibiotic-resistant infections at a global level. Similarly, the Public Health Agency of Canada has introduced the Canadian Antimicrobial Resistance Surveillance System (CARSS) to study drug-resistant infections pattern at the country level.
However, according to a review published by WHO in March 2023, the antibiotics pipeline activities are limited, with only 12 new antibiotics being approved between 2017 and 2021. The review further stated that there are only 27 new candidates under development, out of which only 6 are considered “innovative” enough to be capable of overcoming antibiotic resistance as defined by WHO.
The prevalence of gram-negative infections is increasing at an alarming rate. These infections have lesser treatment options available in the market. The high unmet needs result in high demand for new therapies and, therefore, small and medium-sized pharmaceutical companies are actively involved in the development of novel treatment options. Moreover, the government and other organizations are also aiding research activities to drive the development of innovative therapies.
Multiple mid-level biotechnology companies have entered the arena with targeted therapies for antibiotic-resistant infections. Various manufacturers are developing therapies, especially for drug-resistant infections, that target a smaller population subset.
The U.S. government in alliance with BARDA is supporting several companies to boost the development of new therapies for antibiotic-resistant diseases. BARDA has also been associated with pharmaceutical companies such as GSK; Tetraphase; Basilea; Astra Zeneca; and many more. Many countries and international organizations have formed dedicated groups or alliances to monitor and study the pattern of drug-resistant infections.
For instance, the WHO has introduced the Global Antimicrobial Resistance Surveillance System (GLASS) to monitor antibiotic-resistant infections at a global level. Similarly, the Public Health Agency of Canada has introduced the Canadian Antimicrobial Resistance Surveillance System (CARSS) to study drug-resistant infections pattern at the country level.
However, according to a review published by WHO in March 2023, the antibiotics pipeline activities are limited, with only 12 new antibiotics being approved between 2017 and 2021. The review further stated that there are only 27 new candidates under development, out of which only 6 are considered “innovative” enough to be capable of overcoming antibiotic resistance as defined by WHO.
Antibiotic Resistance Market Report Highlights
- In 2023, cUTI accounted for the largest market share and is anticipated to maintain its dominance in the global market in the coming years
- Combination drugs are expected to grow at the fastest CAGR over the forecast period
- North America dominated the antibiotic resistance industry in 2023. The target goals set by the U.S. national action plan in response to the significant burden of resistant gram-positive and negative infections is the key factor driving the market
- Asia-Pacific is set to witness the fastest growth over the forecast period due to excessive consumption of antibiotics, advancements in technology, and growing awareness about antibiotic resistance testing, treatment, & management of the same.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Pathogen
1.2.3. Drug Class
1.2.4. Mechanism of Action
1.2.5. Distribution Channel
1.2.6. Regional Scope
1.2.7. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Distribution Channels
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.4.5.1. Data for Primary Interviews in North America
1.4.5.2. Data for Primary Interviews in Europe
1.4.5.3. Data for Primary Interviews in Asia-Pacific
1.4.5.4. Data for Primary Interviews in Latin America
1.4.5.5. Data for Primary Interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Distribution Channels
1.9. List of Primary Distribution Channels
1.10. Objectives
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Pathogen
1.2.3. Drug Class
1.2.4. Mechanism of Action
1.2.5. Distribution Channel
1.2.6. Regional Scope
1.2.7. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Distribution Channels
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.4.5.1. Data for Primary Interviews in North America
1.4.5.2. Data for Primary Interviews in Europe
1.4.5.3. Data for Primary Interviews in Asia-Pacific
1.4.5.4. Data for Primary Interviews in Latin America
1.4.5.5. Data for Primary Interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Distribution Channels
1.9. List of Primary Distribution Channels
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease
2.2.2. Pathogen
2.2.3. Drug Class
2.2.4. Mechanism of Action
2.2.5. Distribution Channel
2.2.6. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Disease
2.2.2. Pathogen
2.2.3. Drug Class
2.2.4. Mechanism of Action
2.2.5. Distribution Channel
2.2.6. Regional outlook
2.3. Competitive Insights
Chapter 3. Antibiotic Resistance Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing burden of antibiotic-resistant infections
3.2.1.2. Growing need for new antibiotic therapies
3.2.1.3. Rising public health concern and awareness
3.2.2. Market restraint analysis
3.2.2.1. High cost of therapeutics
3.3. Antibiotic Resistance Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing burden of antibiotic-resistant infections
3.2.1.2. Growing need for new antibiotic therapies
3.2.1.3. Rising public health concern and awareness
3.2.2. Market restraint analysis
3.2.2.1. High cost of therapeutics
3.3. Antibiotic Resistance Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Antibiotic Resistance Market: Disease Estimates & Trend Analysis
4.1. Disease Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Antibiotic Resistance Market by Disease Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. cUTI (Complicated Urinary Tract Infections)
4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. CDI (Clostridioides difficile Infection)
4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. ABSSSI (Acute bacterial skin and skin structure infections)
4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. HABP (Hospital-acquired bacterial pneumonia)
4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.5. CABP (Community-acquired pneumonia)
4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.6. cIAI (Complicated intra-abdominal infection)
4.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.7. BSI (Bloodstream infection
4.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.2. Segment Dashboard
4.3. Global Antibiotic Resistance Market by Disease Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. cUTI (Complicated Urinary Tract Infections)
4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. CDI (Clostridioides difficile Infection)
4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. ABSSSI (Acute bacterial skin and skin structure infections)
4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. HABP (Hospital-acquired bacterial pneumonia)
4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.5. CABP (Community-acquired pneumonia)
4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.6. cIAI (Complicated intra-abdominal infection)
4.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.7. BSI (Bloodstream infection
4.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Antibiotic Resistance Market: Pathogen Estimates & Trend Analysis
5.1. Pathogen Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Antibiotic Resistance Market by Pathogen Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. E. coli
5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. K. pneumoniae
5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3. P. aeruginosa
5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.4. S. aureus
5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.5. A. baumannii
5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.6. S. pneumoniae
5.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.7. H. influenzae
5.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.8. C. difficile
5.4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.9. E. faecium
5.4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.2. Segment Dashboard
5.3. Global Antibiotic Resistance Market by Pathogen Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. E. coli
5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. K. pneumoniae
5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3. P. aeruginosa
5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.4. S. aureus
5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.5. A. baumannii
5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.6. S. pneumoniae
5.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.7. H. influenzae
5.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.8. C. difficile
5.4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.9. E. faecium
5.4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Antibiotic Resistance Market: Drug Class Estimates & Trend Analysis
6.1. Drug Class Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Antibiotic Resistance Market by Drug Class Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Oxazolidinones
6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
6.4.2. Lipoglycopeptides
6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3. Tetracyclines
6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.4. Combination therapies
6.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.5. Cephalosporins
6.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.6. Others
6.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.2. Segment Dashboard
6.3. Global Antibiotic Resistance Market by Drug Class Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Oxazolidinones
6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
6.4.2. Lipoglycopeptides
6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3. Tetracyclines
6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.4. Combination therapies
6.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.5. Cephalosporins
6.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.6. Others
6.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Antibiotic Resistance Market: Mechanism of Action Estimates & Trend Analysis
7.1. Mechanism of Action Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Antibiotic Resistance Market by Mechanism of Action Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Protein Synthesis Inhibitors
7.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
7.4.2. Cell Wall Synthesis Inhibitors
7.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3. RNA Synthesis Inhibitors
7.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD million)
7.4.4. DNA Synthesis Inhibitors
7.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5. Others
7.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.2. Segment Dashboard
7.3. Global Antibiotic Resistance Market by Mechanism of Action Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Protein Synthesis Inhibitors
7.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
7.4.2. Cell Wall Synthesis Inhibitors
7.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3. RNA Synthesis Inhibitors
7.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD million)
7.4.4. DNA Synthesis Inhibitors
7.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5. Others
7.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Antibiotic Resistance Market: Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel Market Share, 2023 & 2030
8.2. Segment Dashboard
8.3. Global Antibiotic Resistance Market by Distribution Channel Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. Hospital Pharmacies
8.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
8.4.2. Retail Pharmacies
8.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.3. Online Pharmacies
8.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.2. Segment Dashboard
8.3. Global Antibiotic Resistance Market by Distribution Channel Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. Hospital Pharmacies
8.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
8.4.2. Retail Pharmacies
8.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.3. Online Pharmacies
8.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Antibiotic Resistance Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2023 & 2030
9.2. Regional Market Dashboard
9.3. Global Regional Market Snapshot
9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
9.5. North America
9.5.1. U.S.
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework/reimbursement structure
9.5.1.3. Competitive scenario
9.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.2. Canada
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework/reimbursement structure
9.5.2.3. Competitive scenario
9.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
9.6. Europe
9.6.1. UK
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework/reimbursement structure
9.6.1.3. Competitive scenario
9.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.2. Germany
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework/reimbursement structure
9.6.2.3. Competitive scenario
9.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.3. France
9.6.3.1. Key country dynamics
9.6.3.2. Regulatory framework/reimbursement structure
9.6.3.3. Competitive scenario
9.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.4. Italy
9.6.4.1. Key country dynamics
9.6.4.2. Regulatory framework/reimbursement structure
9.6.4.3. Competitive scenario
9.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.5. Spain
9.6.5.1. Key country dynamics
9.6.5.2. Regulatory framework/reimbursement structure
9.6.5.3. Competitive scenario
9.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.6. Norway
9.6.6.1. Key country dynamics
9.6.6.2. Regulatory framework/reimbursement structure
9.6.6.3. Competitive scenario
9.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.7. Sweden
9.6.7.1. Key country dynamics
9.6.7.2. Regulatory framework/reimbursement structure
9.6.7.3. Competitive scenario
9.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.8. Denmark
9.6.8.1. Key country dynamics
9.6.8.2. Regulatory framework/reimbursement structure
9.6.8.3. Competitive scenario
9.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
9.7. Asia-Pacific
9.7.1. Japan
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework/reimbursement structure
9.7.1.3. Competitive scenario
9.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.2. China
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework/reimbursement structure
9.7.2.3. Competitive scenario
9.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.3. India
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework/reimbursement structure
9.7.3.3. Competitive scenario
9.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.4. Australia
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework/reimbursement structure
9.7.4.3. Competitive scenario
9.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.5. South Korea
9.7.5.1. Key country dynamics
9.7.5.2. Regulatory framework/reimbursement structure
9.7.5.3. Competitive scenario
9.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.6. Thailand
9.7.6.1. Key country dynamics
9.7.6.2. Regulatory framework/reimbursement structure
9.7.6.3. Competitive scenario
9.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
9.8. Latin America
9.8.1. Brazil
9.8.1.1. Key country dynamics
9.8.1.2. Regulatory framework/reimbursement structure
9.8.1.3. Competitive scenario
9.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
9.8.2. Mexico
9.8.2.1. Key country dynamics
9.8.2.2. Regulatory framework/reimbursement structure
9.8.2.3. Competitive scenario
9.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
9.8.3. Argentina
9.8.3.1. Key country dynamics
9.8.3.2. Regulatory framework/reimbursement structure
9.8.3.3. Competitive scenario
9.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
9.9. MEA
9.9.1. South Africa
9.9.1.1. Key country dynamics
9.9.1.2. Regulatory framework/reimbursement structure
9.9.1.3. Competitive scenario
9.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
9.9.2. Saudi Arabia
9.9.2.1. Key country dynamics
9.9.2.2. Regulatory framework/reimbursement structure
9.9.2.3. Competitive scenario
9.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
9.9.3. UAE
9.9.3.1. Key country dynamics
9.9.3.2. Regulatory framework/reimbursement structure
9.9.3.3. Competitive scenario
9.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
9.9.4. Kuwait
9.9.4.1. Key country dynamics
9.9.4.2. Regulatory framework/reimbursement structure
9.9.4.3. Competitive scenario
9.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
9.2. Regional Market Dashboard
9.3. Global Regional Market Snapshot
9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
9.5. North America
9.5.1. U.S.
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework/reimbursement structure
9.5.1.3. Competitive scenario
9.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
9.5.2. Canada
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework/reimbursement structure
9.5.2.3. Competitive scenario
9.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
9.6. Europe
9.6.1. UK
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework/reimbursement structure
9.6.1.3. Competitive scenario
9.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.2. Germany
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework/reimbursement structure
9.6.2.3. Competitive scenario
9.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.3. France
9.6.3.1. Key country dynamics
9.6.3.2. Regulatory framework/reimbursement structure
9.6.3.3. Competitive scenario
9.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.4. Italy
9.6.4.1. Key country dynamics
9.6.4.2. Regulatory framework/reimbursement structure
9.6.4.3. Competitive scenario
9.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.5. Spain
9.6.5.1. Key country dynamics
9.6.5.2. Regulatory framework/reimbursement structure
9.6.5.3. Competitive scenario
9.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.6. Norway
9.6.6.1. Key country dynamics
9.6.6.2. Regulatory framework/reimbursement structure
9.6.6.3. Competitive scenario
9.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.7. Sweden
9.6.7.1. Key country dynamics
9.6.7.2. Regulatory framework/reimbursement structure
9.6.7.3. Competitive scenario
9.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
9.6.8. Denmark
9.6.8.1. Key country dynamics
9.6.8.2. Regulatory framework/reimbursement structure
9.6.8.3. Competitive scenario
9.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
9.7. Asia-Pacific
9.7.1. Japan
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework/reimbursement structure
9.7.1.3. Competitive scenario
9.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.2. China
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework/reimbursement structure
9.7.2.3. Competitive scenario
9.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.3. India
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework/reimbursement structure
9.7.3.3. Competitive scenario
9.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.4. Australia
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework/reimbursement structure
9.7.4.3. Competitive scenario
9.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.5. South Korea
9.7.5.1. Key country dynamics
9.7.5.2. Regulatory framework/reimbursement structure
9.7.5.3. Competitive scenario
9.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
9.7.6. Thailand
9.7.6.1. Key country dynamics
9.7.6.2. Regulatory framework/reimbursement structure
9.7.6.3. Competitive scenario
9.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
9.8. Latin America
9.8.1. Brazil
9.8.1.1. Key country dynamics
9.8.1.2. Regulatory framework/reimbursement structure
9.8.1.3. Competitive scenario
9.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
9.8.2. Mexico
9.8.2.1. Key country dynamics
9.8.2.2. Regulatory framework/reimbursement structure
9.8.2.3. Competitive scenario
9.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
9.8.3. Argentina
9.8.3.1. Key country dynamics
9.8.3.2. Regulatory framework/reimbursement structure
9.8.3.3. Competitive scenario
9.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
9.9. MEA
9.9.1. South Africa
9.9.1.1. Key country dynamics
9.9.1.2. Regulatory framework/reimbursement structure
9.9.1.3. Competitive scenario
9.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
9.9.2. Saudi Arabia
9.9.2.1. Key country dynamics
9.9.2.2. Regulatory framework/reimbursement structure
9.9.2.3. Competitive scenario
9.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
9.9.3. UAE
9.9.3.1. Key country dynamics
9.9.3.2. Regulatory framework/reimbursement structure
9.9.3.3. Competitive scenario
9.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
9.9.4. Kuwait
9.9.4.1. Key country dynamics
9.9.4.2. Regulatory framework/reimbursement structure
9.9.4.3. Competitive scenario
9.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, by Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company market share analysis, 2023
10.3.4. Melinta Therapeutics
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Disease benchmarking
10.3.4.4. Strategic initiatives
10.3.5. Basilea Pharmaceutica Ltd.
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Disease benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Tetraphase Pharmaceuticals
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Disease benchmarking
10.3.6.4. Strategic initiatives
10.3.7. Theravance Biopharma
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Disease benchmarking
10.3.7.4. Strategic initiatives
10.3.8. WOCKHARDT
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Disease benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Paratek Pharmaceuticals, Inc.
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Disease benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Seres Therapeutics
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Disease benchmarking
10.3.10.4. Strategic initiatives
10.3.11. ACHAOGEN, INC.
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Disease benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Entasis therapeutics
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Disease benchmarking
10.3.12.4. Strategic initiatives
10.3.13. AbbVie
10.3.13.1. Company overview
10.3.13.2. Financial performance
10.3.13.3. Disease benchmarking
10.3.13.4. Strategic initiatives
10.3.14. Merck & Co. Inc.
10.3.14.1. Company overview
10.3.14.2. Financial performance
10.3.14.3. Disease benchmarking
10.3.14.4. Strategic initiatives
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company market share analysis, 2023
10.3.4. Melinta Therapeutics
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Disease benchmarking
10.3.4.4. Strategic initiatives
10.3.5. Basilea Pharmaceutica Ltd.
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Disease benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Tetraphase Pharmaceuticals
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Disease benchmarking
10.3.6.4. Strategic initiatives
10.3.7. Theravance Biopharma
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Disease benchmarking
10.3.7.4. Strategic initiatives
10.3.8. WOCKHARDT
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Disease benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Paratek Pharmaceuticals, Inc.
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Disease benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Seres Therapeutics
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Disease benchmarking
10.3.10.4. Strategic initiatives
10.3.11. ACHAOGEN, INC.
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Disease benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Entasis therapeutics
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Disease benchmarking
10.3.12.4. Strategic initiatives
10.3.13. AbbVie
10.3.13.1. Company overview
10.3.13.2. Financial performance
10.3.13.3. Disease benchmarking
10.3.13.4. Strategic initiatives
10.3.14. Merck & Co. Inc.
10.3.14.1. Company overview
10.3.14.2. Financial performance
10.3.14.3. Disease benchmarking
10.3.14.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America Antibiotic Resistance market, by region, 2018-2030 (USD Million)
Table 3 North America Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 4 North America Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 5 North America Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 6 North America Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 7 North America Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 8 U.S. Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 9 U.S. Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 10 U.S. Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 11 U.S. Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 12 U.S. Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 13 Canada Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 14 Canada Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 15 Canada Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 16 Canada Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 17 Canada Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 18 Europe Antibiotic Resistance market, by region, 2018-2030 (USD Million)
Table 19 Europe Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 20 Europe Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 21 Europe Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 22 Europe Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 23 Europe Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 24 Germany Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 25 Germany Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 26 Germany Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 27 Germany Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 28 Germany Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 29 UK Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 30 UK Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 31 UK Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 32 UK Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 33 UK Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 34 France Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 35 France Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 36 France Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 37 France Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 38 France Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 39 Italy Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 40 Italy Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 41 Italy Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 42 Italy Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 43 Italy Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 44 Spain Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 45 Spain Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 46 Spain Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 47 Spain Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 48 Spain Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 49 Denmark Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 50 Denmark Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 51 Denmark Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 52 Denmark Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 53 Denmark Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 54 Sweden Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 55 Sweden Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 56 Sweden Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 57 Sweden Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 58 Sweden Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 59 Norway Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 60 Norway Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 61 Norway Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 62 Norway Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 63 Norway Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 64 Asia-Pacific Antibiotic Resistance market, by region, 2018-2030 (USD Million)
Table 65 Asia-Pacific Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 66 Asia-Pacific Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 67 Asia-Pacific Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 68 Asia-Pacific Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 69 Asia-Pacific Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 70 China Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 71 China Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 72 China Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 73 China Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 74 China Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 75 Japan Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 76 Japan Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 77 Japan Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 78 Japan Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 79 Japan Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 80 India Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 81 India Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 82 India Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 83 India Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 84 India Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 85 South Korea Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 86 South Korea Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 87 South Korea Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 88 South Korea Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 89 South Korea Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 90 Australia Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 91 Australia Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 92 Australia Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 93 Australia Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 94 Australia Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 95 Thailand Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 96 Thailand Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 97 Thailand Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 98 Thailand Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 99 Thailand Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 100 Latin America Antibiotic Resistance market, by region, 2018-2030 (USD Million)
Table 101 Latin America Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 102 Latin America Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 103 Latin America Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 104 Latin America Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 105 Latin America Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 106 Brazil Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 107 Brazil Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 108 Brazil Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 109 Brazil Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 110 Brazil Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 111 Mexico Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 112 Mexico Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 113 Mexico Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 114 Mexico Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 115 Mexico Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 116 Argentina Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 117 Argentina Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 118 Argentina Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 119 Argentina Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 120 Argentina Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 121 MEA Antibiotic Resistance market, by region, 2018-2030 (USD Million)
Table 122 MEA Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 123 MEA Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 124 MEA Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 125 MEA Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 126 MEA Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 127 South Africa Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 128 South Africa Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 129 South Africa Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 130 South Africa Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 131 South Africa Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 132 Saudi Arabia Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 133 Saudi Arabia Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 134 Saudi Arabia Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 135 Saudi Arabia Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 136 Saudi Arabia Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 137 UAE Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 138 UAE Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 139 UAE Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 140 UAE Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 141 UAE Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 142 Kuwait Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 143 Kuwait Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 144 Kuwait Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 145 Kuwait Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 146 Kuwait Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 2 North America Antibiotic Resistance market, by region, 2018-2030 (USD Million)
Table 3 North America Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 4 North America Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 5 North America Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 6 North America Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 7 North America Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 8 U.S. Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 9 U.S. Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 10 U.S. Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 11 U.S. Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 12 U.S. Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 13 Canada Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 14 Canada Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 15 Canada Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 16 Canada Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 17 Canada Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 18 Europe Antibiotic Resistance market, by region, 2018-2030 (USD Million)
Table 19 Europe Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 20 Europe Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 21 Europe Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 22 Europe Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 23 Europe Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 24 Germany Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 25 Germany Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 26 Germany Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 27 Germany Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 28 Germany Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 29 UK Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 30 UK Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 31 UK Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 32 UK Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 33 UK Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 34 France Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 35 France Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 36 France Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 37 France Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 38 France Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 39 Italy Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 40 Italy Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 41 Italy Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 42 Italy Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 43 Italy Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 44 Spain Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 45 Spain Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 46 Spain Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 47 Spain Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 48 Spain Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 49 Denmark Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 50 Denmark Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 51 Denmark Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 52 Denmark Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 53 Denmark Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 54 Sweden Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 55 Sweden Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 56 Sweden Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 57 Sweden Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 58 Sweden Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 59 Norway Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 60 Norway Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 61 Norway Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 62 Norway Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 63 Norway Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 64 Asia-Pacific Antibiotic Resistance market, by region, 2018-2030 (USD Million)
Table 65 Asia-Pacific Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 66 Asia-Pacific Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 67 Asia-Pacific Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 68 Asia-Pacific Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 69 Asia-Pacific Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 70 China Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 71 China Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 72 China Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 73 China Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 74 China Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 75 Japan Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 76 Japan Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 77 Japan Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 78 Japan Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 79 Japan Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 80 India Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 81 India Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 82 India Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 83 India Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 84 India Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 85 South Korea Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 86 South Korea Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 87 South Korea Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 88 South Korea Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 89 South Korea Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 90 Australia Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 91 Australia Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 92 Australia Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 93 Australia Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 94 Australia Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 95 Thailand Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 96 Thailand Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 97 Thailand Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 98 Thailand Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 99 Thailand Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 100 Latin America Antibiotic Resistance market, by region, 2018-2030 (USD Million)
Table 101 Latin America Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 102 Latin America Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 103 Latin America Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 104 Latin America Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 105 Latin America Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 106 Brazil Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 107 Brazil Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 108 Brazil Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 109 Brazil Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 110 Brazil Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 111 Mexico Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 112 Mexico Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 113 Mexico Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 114 Mexico Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 115 Mexico Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 116 Argentina Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 117 Argentina Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 118 Argentina Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 119 Argentina Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 120 Argentina Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 121 MEA Antibiotic Resistance market, by region, 2018-2030 (USD Million)
Table 122 MEA Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 123 MEA Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 124 MEA Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 125 MEA Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 126 MEA Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 127 South Africa Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 128 South Africa Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 129 South Africa Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 130 South Africa Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 131 South Africa Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 132 Saudi Arabia Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 133 Saudi Arabia Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 134 Saudi Arabia Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 135 Saudi Arabia Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 136 Saudi Arabia Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 137 UAE Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 138 UAE Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 139 UAE Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 140 UAE Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 141 UAE Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
Table 142 Kuwait Antibiotic Resistance market, by disease, 2018-2030 (USD Million)
Table 143 Kuwait Antibiotic Resistance market, by pathogen, 2018-2030 (USD Million)
Table 144 Kuwait Antibiotic Resistance market, by drug class, 2018-2030 (USD Million)
Table 145 Kuwait Antibiotic Resistance market, by mechanism of action, 2018-2030 (USD Million)
Table 146 Kuwait Antibiotic Resistance market, by distribution channel, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Antibiotic Resistance market: market outlook
Fig. 14 Antibiotic Resistance competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Antibiotic Resistance market driver impact
Fig. 20 Antibiotic Resistance market restraint impact
Fig. 21 Antibiotic Resistance market strategic initiatives analysis
Fig. 22 Antibiotic Resistance market: Disease movement analysis
Fig. 23 Antibiotic Resistance market: Disease outlook and key takeaways
Fig. 24 cUTI Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 25 CDI Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 26 ABSSSI Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 27 HABP Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 28 CABP Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 29 cIAI Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 30 BSI Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 31 Antibiotic Resistance Market: Pathogen movement Analysis
Fig. 32 Antibiotic Resistance market: Pathogen outlook and key takeaways
Fig. 33 E. coli market estimates and forecasts, 2018-2030
Fig. 34 K. pneumoniae market estimates and forecasts,2018-2030
Fig. 35 P. aeruginosa market estimates and forecasts, 2018-2030
Fig. 36 S. aureus market estimates and forecasts,2018-2030
Fig. 37 A. baumannii market estimates and forecasts, 2018-2030
Fig. 38 S. pneumoniae market estimates and forecasts,2018-2030
Fig. 39 H. influenzae market estimates and forecasts, 2018-2030
Fig. 40 C. difficile market estimates and forecasts,2018-2030
Fig. 41 E. faecium market estimates and forecasts, 2018-2030
Fig. 42 Antibiotic Resistance market: Drug Class movement analysis
Fig. 43 Antibiotic Resistance market: Drug Class outlook and key takeaways
Fig. 44 Oxazolidinones market estimates and forecasts, 2018-2030
Fig. 45 Lipoglycopeptides market estimates and forecasts,2018-2030
Fig. 46 Tetracyclines market estimates and forecasts,2018-2030
Fig. 47 Combination therapies market estimates and forecasts,2018-2030
Fig. 48 Cephalosporins market estimates and forecasts,2018-2030
Fig. 49 Others market estimates and forecasts,2018-2030
Fig. 50 Antibiotic Resistance market: Mechanism of Action movement analysis
Fig. 51 Antibiotic Resistance market: Mechanism of Action outlook and key takeaways
Fig. 52 Protein Synthesis Inhibitors market estimates and forecasts, 2018-2030
Fig. 53 Cell Wall Synthesis Inhibitors market estimates and forecasts,2018-2030
Fig. 54 RNA Synthesis Inhibitors market estimates and forecasts, 2018-2030
Fig. 55 DNA Synthesis Inhibitors market estimates and forecasts,2018-2030
Fig. 56 Others Inhibitors market estimates and forecasts,2018-2030
Fig. 57 Antibiotic Resistance market: Distribution Channel movement analysis
Fig. 58 Antibiotic Resistance market: Distribution Channel outlook and key takeaways
Fig. 59 Hospital Pharmacies market estimates and forecasts, 2018-2030
Fig. 60 Retail Pharmacies market estimates and forecasts,2018-2030
Fig. 61 Online Pharmacies market estimates and forecasts,2018-2030
Fig. 62 Global Antibiotic Resistance market: Regional movement analysis
Fig. 63 Global Antibiotic Resistance market: Regional outlook and key takeaways
Fig. 64 Global Antibiotic Resistance market share and leading players
Fig. 65 North America market share and leading players
Fig. 66 Europe market share and leading players
Fig. 67 Asia-Pacific market share and leading players
Fig. 68 Latin America market share and leading players
Fig. 69 Middle East & Africa market share and leading players
Fig. 70 North America: SWOT
Fig. 71 Europe SWOT
Fig. 72 Asia-Pacific SWOT
Fig. 73 Latin America SWOT
Fig. 74 MEA SWOT
Fig. 75 North America
Fig. 76 North America market estimates and forecasts, 2018-2030
Fig. 77 U.S.
Fig. 78 U.S. market estimates and forecasts, 2018-2030
Fig. 79 Canada
Fig. 80 Canada market estimates and forecasts, 2018-2030
Fig. 81 Europe
Fig. 82 Europe market estimates and forecasts, 2018-2030
Fig. 83 UK
Fig. 84 UK market estimates and forecasts, 2018-2030
Fig. 85 Germany
Fig. 86 Germany market estimates and forecasts, 2018-2030
Fig. 87 France
Fig. 88 France market estimates and forecasts, 2018-2030
Fig. 89 Italy
Fig. 90 Italy market estimates and forecasts, 2018-2030
Fig. 91 Spain
Fig. 92 Spain market estimates and forecasts, 2018-2030
Fig. 93 Denmark
Fig. 94 Denmark market estimates and forecasts, 2018-2030
Fig. 95 Sweden
Fig. 96 Sweden market estimates and forecasts, 2018-2030
Fig. 97 Norway
Fig. 98 Norway market estimates and forecasts, 2018-2030
Fig. 99 Asia-Pacific
Fig. 100 Asia-Pacific market estimates and forecasts, 2018-2030
Fig. 101 China
Fig. 102 China market estimates and forecasts, 2018-2030
Fig. 103 Japan
Fig. 104 Japan market estimates and forecasts, 2018-2030
Fig. 105 India
Fig. 106 India market estimates and forecasts, 2018-2030
Fig. 107 Thailand
Fig. 108 Thailand market estimates and forecasts, 2018-2030
Fig. 109 South Korea
Fig. 110 South Korea market estimates and forecasts, 2018-2030
Fig. 111 Australia
Fig. 112 Australia market estimates and forecasts, 2018-2030
Fig. 113 Latin America
Fig. 114 Latin America market estimates and forecasts, 2018-2030
Fig. 115 Brazil
Fig. 116 Brazil market estimates and forecasts, 2018-2030
Fig. 117 Mexico
Fig. 118 Mexico market estimates and forecasts, 2018-2030
Fig. 119 Argentina
Fig. 120 Argentina market estimates and forecasts, 2018-2030
Fig. 121 Middle East and Africa
Fig. 122 Middle East and Africa market estimates and forecasts, 2018-2030
Fig. 123 South Africa
Fig. 124 South Africa market estimates and forecasts, 2018-2030
Fig. 125 Saudi Arabia
Fig. 126 Saudi Arabia market estimates and forecasts, 2018-2030
Fig. 127 UAE
Fig. 128 UAE market estimates and forecasts, 2018-2030
Fig. 129 Kuwait
Fig. 130 Kuwait market estimates and forecasts, 2018-2030
Fig. 131 Market share of key market players- Antibiotic Resistance market
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Antibiotic Resistance market: market outlook
Fig. 14 Antibiotic Resistance competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Antibiotic Resistance market driver impact
Fig. 20 Antibiotic Resistance market restraint impact
Fig. 21 Antibiotic Resistance market strategic initiatives analysis
Fig. 22 Antibiotic Resistance market: Disease movement analysis
Fig. 23 Antibiotic Resistance market: Disease outlook and key takeaways
Fig. 24 cUTI Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 25 CDI Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 26 ABSSSI Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 27 HABP Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 28 CABP Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 29 cIAI Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 30 BSI Antibiotic Resistance market estimates and forecast, 2018-2030
Fig. 31 Antibiotic Resistance Market: Pathogen movement Analysis
Fig. 32 Antibiotic Resistance market: Pathogen outlook and key takeaways
Fig. 33 E. coli market estimates and forecasts, 2018-2030
Fig. 34 K. pneumoniae market estimates and forecasts,2018-2030
Fig. 35 P. aeruginosa market estimates and forecasts, 2018-2030
Fig. 36 S. aureus market estimates and forecasts,2018-2030
Fig. 37 A. baumannii market estimates and forecasts, 2018-2030
Fig. 38 S. pneumoniae market estimates and forecasts,2018-2030
Fig. 39 H. influenzae market estimates and forecasts, 2018-2030
Fig. 40 C. difficile market estimates and forecasts,2018-2030
Fig. 41 E. faecium market estimates and forecasts, 2018-2030
Fig. 42 Antibiotic Resistance market: Drug Class movement analysis
Fig. 43 Antibiotic Resistance market: Drug Class outlook and key takeaways
Fig. 44 Oxazolidinones market estimates and forecasts, 2018-2030
Fig. 45 Lipoglycopeptides market estimates and forecasts,2018-2030
Fig. 46 Tetracyclines market estimates and forecasts,2018-2030
Fig. 47 Combination therapies market estimates and forecasts,2018-2030
Fig. 48 Cephalosporins market estimates and forecasts,2018-2030
Fig. 49 Others market estimates and forecasts,2018-2030
Fig. 50 Antibiotic Resistance market: Mechanism of Action movement analysis
Fig. 51 Antibiotic Resistance market: Mechanism of Action outlook and key takeaways
Fig. 52 Protein Synthesis Inhibitors market estimates and forecasts, 2018-2030
Fig. 53 Cell Wall Synthesis Inhibitors market estimates and forecasts,2018-2030
Fig. 54 RNA Synthesis Inhibitors market estimates and forecasts, 2018-2030
Fig. 55 DNA Synthesis Inhibitors market estimates and forecasts,2018-2030
Fig. 56 Others Inhibitors market estimates and forecasts,2018-2030
Fig. 57 Antibiotic Resistance market: Distribution Channel movement analysis
Fig. 58 Antibiotic Resistance market: Distribution Channel outlook and key takeaways
Fig. 59 Hospital Pharmacies market estimates and forecasts, 2018-2030
Fig. 60 Retail Pharmacies market estimates and forecasts,2018-2030
Fig. 61 Online Pharmacies market estimates and forecasts,2018-2030
Fig. 62 Global Antibiotic Resistance market: Regional movement analysis
Fig. 63 Global Antibiotic Resistance market: Regional outlook and key takeaways
Fig. 64 Global Antibiotic Resistance market share and leading players
Fig. 65 North America market share and leading players
Fig. 66 Europe market share and leading players
Fig. 67 Asia-Pacific market share and leading players
Fig. 68 Latin America market share and leading players
Fig. 69 Middle East & Africa market share and leading players
Fig. 70 North America: SWOT
Fig. 71 Europe SWOT
Fig. 72 Asia-Pacific SWOT
Fig. 73 Latin America SWOT
Fig. 74 MEA SWOT
Fig. 75 North America
Fig. 76 North America market estimates and forecasts, 2018-2030
Fig. 77 U.S.
Fig. 78 U.S. market estimates and forecasts, 2018-2030
Fig. 79 Canada
Fig. 80 Canada market estimates and forecasts, 2018-2030
Fig. 81 Europe
Fig. 82 Europe market estimates and forecasts, 2018-2030
Fig. 83 UK
Fig. 84 UK market estimates and forecasts, 2018-2030
Fig. 85 Germany
Fig. 86 Germany market estimates and forecasts, 2018-2030
Fig. 87 France
Fig. 88 France market estimates and forecasts, 2018-2030
Fig. 89 Italy
Fig. 90 Italy market estimates and forecasts, 2018-2030
Fig. 91 Spain
Fig. 92 Spain market estimates and forecasts, 2018-2030
Fig. 93 Denmark
Fig. 94 Denmark market estimates and forecasts, 2018-2030
Fig. 95 Sweden
Fig. 96 Sweden market estimates and forecasts, 2018-2030
Fig. 97 Norway
Fig. 98 Norway market estimates and forecasts, 2018-2030
Fig. 99 Asia-Pacific
Fig. 100 Asia-Pacific market estimates and forecasts, 2018-2030
Fig. 101 China
Fig. 102 China market estimates and forecasts, 2018-2030
Fig. 103 Japan
Fig. 104 Japan market estimates and forecasts, 2018-2030
Fig. 105 India
Fig. 106 India market estimates and forecasts, 2018-2030
Fig. 107 Thailand
Fig. 108 Thailand market estimates and forecasts, 2018-2030
Fig. 109 South Korea
Fig. 110 South Korea market estimates and forecasts, 2018-2030
Fig. 111 Australia
Fig. 112 Australia market estimates and forecasts, 2018-2030
Fig. 113 Latin America
Fig. 114 Latin America market estimates and forecasts, 2018-2030
Fig. 115 Brazil
Fig. 116 Brazil market estimates and forecasts, 2018-2030
Fig. 117 Mexico
Fig. 118 Mexico market estimates and forecasts, 2018-2030
Fig. 119 Argentina
Fig. 120 Argentina market estimates and forecasts, 2018-2030
Fig. 121 Middle East and Africa
Fig. 122 Middle East and Africa market estimates and forecasts, 2018-2030
Fig. 123 South Africa
Fig. 124 South Africa market estimates and forecasts, 2018-2030
Fig. 125 Saudi Arabia
Fig. 126 Saudi Arabia market estimates and forecasts, 2018-2030
Fig. 127 UAE
Fig. 128 UAE market estimates and forecasts, 2018-2030
Fig. 129 Kuwait
Fig. 130 Kuwait market estimates and forecasts, 2018-2030
Fig. 131 Market share of key market players- Antibiotic Resistance market
Companies Mentioned
- Melinta Therapeutics
- Basilea Pharmaceutica Ltd.
- Tetraphase Pharmaceuticals
- Theravance Biopharma
- WOCKHARDT
- Paratek Pharmaceuticals, Inc.
- Seres Therapeutics
- ACHAOGEN, INC.
- Entasis therapeutics
- AbbVie
- Merck & Co. Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | January 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 8.72 Billion |
| Forecasted Market Value ( USD | $ 12.48 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
